Efficacy and safety of hybrid therapy combined with branched-chain amino acid and resistance training in frail CKD patients with cardiovascular disease

Efficacy and safety of hybrid therapy combined with branched-chain amino acid and resistance training in frail CKD patients with cardiovascular disease - Branched-chain amino acid and resistance training in frail CKD patients with cardiovascular disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034733

Enrollment

Registered

2018-11-01

Start date

2020-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frail CKD patients with cardiovascular disease

Interventions

Intervention: BCAA suplementation + resistance training, 12weeks, 2-3/week control: placebo + resistance training, 12weeks, 2-3/week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients (eGFR is below 60ml/min/1.73m2) with cardiovascular disease who participate in the outpatients cardiac rehabilitation program

Exclusion criteria

Exclusion criteria: Dysphagia, Severe mobility limitations due to stroke or orthopedic disease, Uncontrolled cardiovascular disease, Diagnosis or treatment of cancer,Cognitive impairment; MOCA-J is above 26points

Design outcomes

Primary

Measure	Time frame
Change in skeletal muscle mass after 12-week intervention	—

Secondary

Measure	Time frame
Muscle strength: handgrip strength and isomertic leg strength Short physical performance battery (SPPB) Sarcopenia: AWGS criteria Frailty: J-CHS, Essential frail toolkit eGFR: serum creatinin, cystatin C	—

Countries

Japan

Contacts

Public ContactMasakazu Saitoh

Sakakibara Heart Institute Department of Rehabilitation

msaitoh@shi.heart.or.jp042-314-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026